Personalis, Inc. · NASDAQ:PSNL
Personalis — Merger or Acquisition (July 2026)
11 slides from Personalis's merger presentation, Jul 20, 2026
Slide 1: Acquisition of Personalis, Inc. Investor Presentation
Acquisition of Personalis, Inc. Investor Presentation July 20, 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “cause,” “continue,” “could,” “depend,” “develop,” “estimates,” “expects,” “fo
Slide 3: Tempus to acquire Personalis, integrating ultrasensitive MRD into its precision oncology platform
Tempus to acquire Personalis, more tightly integrating ultrasensitive Molecular Residual Disease (MRD) into its AI-enabled precision oncology platform MRD Market Expansion Comprehensive Portfolio Volume Acceleration Expands participation in $20+ Creates a comprehensive Accelerates test volume growth
Slide 4: Personalis' Technology Led to the Launch of Four Industry Leading Products
Personalis’ Technology Led to the Launch of Four Industry Leading Products Early Recurrence Detection Precise Genetic Analysis 35,000+ Tests Delivered Detecting cancer recurrence Revealing the unique genetic significantly earlier than signatures of solid tumors standard methods ~1,800 Unique DNA Mark
Slide 5: Personalis' portfolio further expands our comprehensive diagnostics business
Personalis’ portfolio further expands our comprehensive diagnostics business spanning hereditary risk, therapy selection, and MRD & monitoring Tailored testing* Therapy selection Hereditary risk xT, xF Tissue + Liquid Biopsy HRD UGT1A1 DPYD MRD & disease assessment IPS TO PurIST™ MMR monitoring xR D
Slide 6: Early MRD Detection is a Sizable, High-Value Market Opportunity
Early MRD Detection is a Sizable, High-Value Market Opportunity Value Proposition of MRD Market Opportunity Finding Answers Sooner > $20 Billion Leads to Improved Patient Outcomes Total Addressable Market (TAM) in U.S. Less than 10% penetration across most Early intervention and personalized treatme
Slide 7: xM (NeXT Personal Dx) Tumor-Informed
xM (NeXT Personal® Dx) 1 TUMOR-INFORMED Utilizes a tumor-informed methodology and provides a personalized assessment Tumor-informed, ultra sensitive whole of residual disease based on information specific to the patient’s tumor DNA genome assay for solid tumors. ● Detect recurrence 5 to 15 months ear
Slide 8: Leveraging our established infrastructure to meet a massive, high-growth market opportunity
Leveraging our established infrastructure to meet a massive, high-growth market opportunity Initial rollout gives us confidence in commercial potential ~65% 5K+ Of academic medical healthcare institutions systems in the U.S. are connected to Tempus connected to Tempus >55% ~1M Of oncologists in the U
Slide 9: Clinical Test Volumes To Date Give Us Confidence in Broad Launch
Clinical Test Volumes To Date Give Us Confidence in Broad Launch Includes all molecular tests (NeXT Personal Dx & NeXT Dx) “Win-in-MRD” with high growth Q2 Sequential 33% quarter growth Q2 test volume 10,384 Total tests to date >35,000
Slide 10: Data Strategy: Expanding the Data Flywheel
Data Strategy Genomic assays Expanding the Data Flywheel Tissue profiling with Longitudinal MRD Insights Liquid biopsy MRD MRD data extends patient follow-up beyond Multimodal RWD Digital Pathology diagnosis and treatment. New products ML Algos & product This expansion creates a unique longitudinal d
Slide 11: Transaction Overview
Transaction Overview • Tempus AI will acquire all of the outstanding shares of Personalis’ common stock not already owned by Tempus AI at a price of $16.25 per share, representing a 6% premium to their closing (1) price on July 17, 2026 and a 28% premium to unaffected 30-day VWAP Transaction • Resul